Mycoprotein Patent Landscape
Identifiers
Which organizations and claims shape current development around Mycoprotein?
Meatless B V is the organization behind the recent patent EP4626249A1, which claims a method for preparing a mycoprotein food product. The claims focus on a multi-step process: preparing a pre-mix with mycoprotein, plant protein, alginate, and water; shaping it; curing a skin layer with a calcium solution; forming individual shapes while preserving the skin; and then further curing those shapes with a second calcium solution. Additional claims specify the skin thickness (up to 50% of cross-section, preferably 1–5%), low-temperature curing (3–10°C), and forming by tearing or cutting. These claims indicate a product-centric approach to mycoprotein processing.
How is Mycoprotein innovation changing?
Monthly patent filings
Which technical problems do recent patents address with Mycoprotein?
Recent patents address the technical problem of producing mycoprotein-based food products with defined shape and structural integrity. The method in EP4626249A1 solves the challenge of forming individual shapes from a mycoprotein pre-mix by applying a two-stage calcium curing process: first curing only a skin layer, then cutting or tearing the pre-mix into individual shapes while preserving that skin, followed by a second curing step. This approach enables the production of discrete, stable pieces from a mycoprotein-alginate matrix, overcoming issues related to maintaining product form during processing.
How do recent patents change the role or application of Mycoprotein?
Recent patents position mycoprotein as the main structural component of a food product, rather than as a minor ingredient or protein supplement. In EP4626249A1, mycoprotein is combined with a plant protein source and alginate to form a pre-mix that is shaped and cured into individual food pieces. This represents a shift toward using mycoprotein as a primary building block for product architecture, with the alginate acting as a gelling agent to enable the curing process. The broad concentration range (5% to 97%) indicates flexibility in formulation, allowing mycoprotein to dominate the product matrix.
Which product categories and formulation strategies emerge in recent work on Mycoprotein?
The emerging product category is a mycoprotein-based food product, likely in the meat alternative space, given the assignee Meatless B V. The formulation strategy centers on a pre-mix of mycoprotein, plant protein, alginate, and water, which is shaped and then cured using calcium solutions. A key innovation is the two-step curing process: a brief first contact to form a skin, followed by cutting or tearing into individual shapes, and a second curing step at low temperatures (3–10°C) to set the final structure. This approach allows for precise control over shape and texture while maintaining a high mycoprotein content.
Where is the evidence-backed white space for further development of Mycoprotein?
The evidence suggests white space in optimizing the skin-curing parameters for different product formats. The patent claims specify skin thickness ranges (0.1–20% of cross-section) and low-temperature second curing (3–10°C), but do not explore variations in calcium concentration, contact times, or the use of different plant protein sources. Additionally, the broad mycoprotein concentration range (5–97%) leaves room for developing products with lower or higher protein content tailored to specific textures or nutritional profiles. Further innovation could also focus on scaling the tearing/cutting step for industrial production while maintaining skin integrity.